A chemically defined synthetic vaccine model for HIV-1

Area of Science:

• Immunology
• Vaccinology
• Synthetic Biology

Background:

• The development of effective HIV-1 vaccines is crucial.
• Synthetic peptide vaccines offer a defined alternative to traditional carrier-dependent approaches.
• The Multiple Antigenic Peptide (MAP) system allows for the construction of multivalent vaccines without protein carriers.

Purpose of the Study:

• To evaluate the immunogenicity of synthetic peptides from the V3 region of HIV-1 gp120 using the MAP system.
• To compare the immune responses elicited by monoepitope and diepitope MAP constructs in different animal species.
• To assess the potential of these MAP constructs as synthetic HIV-1 vaccine candidates.

Main Methods:

• Synthetic peptides from the V3 loop of HIV-1 gp120 (IIIB, RF, MN isolates) were prepared as monoepitope and diepitope MAPs.
• MAP constructs varied in chain length (11-24 residues) and included a T-helper cell epitope in diepitope designs.
• Immunogenicity was assessed by measuring antibody responses in rabbits, mice, and guinea pigs, including ELISA and virus-dependent cell fusion inhibition assays.

Main Results:

• Antibody response to monoepitope MAPs was species-dependent, with rabbits showing broader reactivity than mice.
• Diepitope MAPs were immunogenic in all tested species, eliciting higher antibody titers than monoepitope MAPs.
• Antibody responses were largely type-specific to the HIV-1 isolate, with some cross-reactivity between IIIB and RF strains. Sera inhibited virus-dependent cell fusion.

Conclusions:

• The MAP system, without protein carriers, can elicit significant antibody responses against synthetic HIV-1 V3 peptides.
• Diepitope MAP constructs demonstrate enhanced immunogenicity compared to monoepitope designs.
• These findings support the potential utility of chemically defined MAP constructs for developing synthetic HIV-1 vaccine candidates.